United States CAR-T Cell Therapy Market By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others), By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Ly
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUnited States CAR-T Cell Therapy Market By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others), By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Ly
United States CAR-T Cell Therapy Market is expected to grow at an impressive rate during the forecast period, 2024-2028.
According to Leukemia and Lymphoma Society, in 2021, an estimated 34,920 new cases of myeloma (19,320 males and 15,600 females) were expected to be diagnosed in the United States (U.S.), and an estimated 138,415 people are living with myeloma in U.S. Additionally, in 2021, 61,090 people were expected to be diagnosed with leukemia in the U.S., and an estimated 397,501 people are living with leukemia in the U.S.
The Chimeric Antigen Receptor (CAR) T-cell therapy is for the treatment of hematologic malignancies i.e., the cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system like leukemia, lymphoma, and multiple myeloma, etc. Another factor driving the market growth is the increasing demand for personalized and targeted cancer therapies. CAR-T cell therapy is a highly personalized treatment that involves modifying the patient's immune cells to target cancer cells, making it a more effective and precise treatment option for certain types of cancers.
According to Global Cancer Observatory, in 2020, around
Rising Prevalence of Cancer
For instance, an estimated 1,519,907 people in the United States are suffering with leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPNs)
Recent Developments
In 2017, the first two autologous CAR T-cell therapies were approved by the US Food and Drug Administration namely tisagenlecleucel (Kymriah) for the treatment of patients up to 25 years of age with large B-cell lymphoma (refractory or in second or later relapse), and axicabtagene ciloleucel (Yescarta),
In 2020, the FDA had given the approval for brexucabtagene autoleucel (TecartusTM) or the treatment of adults with r/r MCL and adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Additionally, in 2021, the FDA had given the approval for Lisocabtagene maraleucel (Breyanzi)
Recently, in March 2022, Ciltacabtagene autoleucel (CarvyktiTM) were approved by FDA for the treatment of adult patients with relapsed or refractory multiple myeloma who have already tried four or more prior lines of therapy.
Commercialization of CAR-T Cell Therapy
The commercialization of CAR-T Cell Therapy is the key challenge resulting in restricting the growth of the market in the forecast period. This is due to the complex manufacturing and supply chain, high-touch commercial model, and reimbursement cost. All CAR T-cell therapies
Increasing Investments in Research and Development & Favorable Regulatory Environment
Research and development are crucial for the advancement of CAR-T cell therapy. The United States has a significant advantage in this regard, as it is home to some of the world's leading research institutions and pharmaceutical companies. These companies are investing heavily in CAR-T cell therapy research, which is driving the market's growth. Additionally, the FDA discovered an improved environment to give approval of two CAR-T cell therapies for use in the United States, which has provided a boost to the market. The regulatory environment for CAR-T cell therapy is favorable, which has encouraged more companies to invest in this area. The FDA's expedited review process for breakthrough therapies has helped speed up the approval process for CAR-T cell therapies, which has contributed to market growth.
Market Segmentation
The United States CAR-T Cell Therapy Market can be segmented
Market Players
Gilead Sciences, Inc (US), Novartis United States, AbbVie Inc., Myriad Genetics, NeoGenomics Laboratories, Intellia Therapeutics (US), Agilent Technologies, Inc. (US), Abcam plc., Bio-Techne. (ExoDx), Sangamo Therapeutics, Inc. (US) etc.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2022 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, Volume Units and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, Volume forecast company share, competitive landscape, growth factors, and trends |
| Segments covered | Product Type Tumor Type Indication Treatment Type Targeted Antigen End User Region Company |
| Regional scope | Northeast Region, Midwest Region, South Region, West Region |
| Key companies profiled | Gilead Sciences, Inc (US), Novartis United States, AbbVie Inc., Myriad Genetics, NeoGenomics Laboratories, Intellia Therapeutics (US), Agilent Technologies, Inc. (US), Abcam plc., Bio-Techne. (ExoDx), Sangamo Therapeutics, Inc. (US). |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy